{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:07:43Z","timestamp":1780524463541,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"49","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.vaccine.2020.10.008","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T22:57:43Z","timestamp":1603234663000},"page":"7850-7857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands"],"prefix":"10.1016","volume":"38","author":[{"given":"W.","family":"Freudenburg-de Graaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Knol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"van der Ende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2020.10.008_b0005","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3201\/eid1904.111799","article-title":"Description and Nomenclature of Neisseria meningitidis Capsule Locus","volume":"19","author":"Harrison","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"20","key":"10.1016\/j.vaccine.2020.10.008_b0010","first-page":"30378","article-title":"The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination","volume":"S0163\u20134453","author":"Parikh","year":"2020","journal-title":"J Infect"},{"issue":"16","key":"10.1016\/j.vaccine.2020.10.008_b0015","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMra0906357","article-title":"Advances in the Development of Vaccines against Neisseria meningitidis","volume":"362","author":"Tan","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.008_b0020","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1901229","article-title":"Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England","volume":"382","author":"Ladhani","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.10.008_b0025","unstructured":"Gezondheidsraad. Vaccinatie tegen meningokokken. Den Haag: Gezondheidsraad; 2018. Report No.: 2018\/28."},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.008_b0030","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1473-3099(18)30048-3","article-title":"Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis","volume":"18","author":"Flacco","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2020.10.008_b0035","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.10.008_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/353461","article-title":"Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes","volume":"2015","author":"Domnich","year":"2015","journal-title":"J Immunol Res"},{"issue":"7","key":"10.1016\/j.vaccine.2020.10.008_b0045","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.vaccine.2018.12.061","article-title":"Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide","volume":"37","author":"Muzzi","year":"2019","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2020.10.008_b0050","article-title":"Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index: a Rapid and Accessible Tool that Exploits Genomic Data in Public Health and Clinical Microbiology Applications","volume":"08","author":"Rodrigues","year":"2020","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.008_b0055","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-4513-2","article-title":"Evaluation of the surveillance system for invasive meningococcal disease (IMD) in the Netherlands, 2004\u20132016","volume":"19","author":"Brandwagt","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.008_b0060","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF02538460","article-title":"Serological typing of meningococci by means of micro-precipitation","volume":"27","author":"Slaterus","year":"1961","journal-title":"Antonie Van Leeuwenhoek"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.008_b0065","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3201\/eid1004.030247","article-title":"PorA Variable Regions of Neisseria meningitidis","volume":"10","author":"Russell","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2020.10.008_b0070","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1099\/mic.0.26131-0","article-title":"Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component","volume":"149","author":"Thompson","year":"2003","journal-title":"Microbiology"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.008_b0075","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1186\/1471-2164-15-1138","article-title":"A gene-by-gene population genomics platform: de novo assembly, annotation and genealogical analysis of 108 representative Neisseria meningitidis genomes","volume":"15","author":"Bratcher","year":"2014","journal-title":"BMC Genomics"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.008_b0080","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-11-595","article-title":"BIGSdb: Scalable analysis of bacterial genome variation at the population level","volume":"11","author":"Jolley","year":"2010","journal-title":"BMC Bioinf"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.008_b0085","doi-asserted-by":"crossref","first-page":"20379","DOI":"10.2807\/ese.18.04.20379-en","article-title":"Automated extraction of typing information for bacterial pathogens from whole genome sequence data: Neisseria meningitidis as an exemplar","volume":"18","author":"Jolley","year":"2013","journal-title":"Euro Surveill"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.008_b0090","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/bioinformatics\/14.1.68","article-title":"SplitsTree: analyzing and visualizing evolutionary data","volume":"14","author":"Huson","year":"1998","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.vaccine.2020.10.008_b0095","first-page":"119","article-title":"Approximate is better than \u201cexact\u201d for interval estimation of binomial proportions","volume":"52","author":"Agresti","year":"1998","journal-title":"Am Stat"},{"issue":"7","key":"10.1016\/j.vaccine.2020.10.008_b0100","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S1473-3099(17)30170-6","article-title":"Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007\u201308 and 2014\u201315: a qualitative and quantitative assessment","volume":"17","author":"Parikh","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2020.10.008_b0105","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1128\/CVI.00133-14","article-title":"Implications of Differential Age Distribution of Disease-Associated Meningococcal Lineages for Vaccine Development","volume":"21","author":"Brehony","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.008_b0110","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/INF.0000000000001056","article-title":"Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age:","volume":"35","author":"Snape","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"15","key":"10.1016\/j.vaccine.2020.10.008_b0115","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose","volume":"185","author":"Snape","year":"2013","journal-title":"Can Med Assoc J"},{"issue":"32","key":"10.1016\/j.vaccine.2020.10.008_b0120","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1016\/j.vaccine.2015.06.079","article-title":"Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children","volume":"33","author":"Vesikari","year":"2015","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2020.10.008_b0125","doi-asserted-by":"crossref","first-page":"E215","DOI":"10.1503\/cmaj.141200","article-title":"Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months","volume":"187","author":"McQuaid","year":"2015","journal-title":"CMAJ"},{"issue":"7","key":"10.1016\/j.vaccine.2020.10.008_b0130","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000000327","article-title":"Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age:","volume":"33","author":"McQuaid","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"41","key":"10.1016\/j.vaccine.2020.10.008_b0135","doi-asserted-by":"crossref","first-page":"E1276","DOI":"10.1503\/cmaj.161288","article-title":"Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules","volume":"189","author":"Sadarangani","year":"2017","journal-title":"CMAJ"},{"issue":"9","key":"10.1016\/j.vaccine.2020.10.008_b0140","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciu601","article-title":"A Decade of Herd Protection After Introduction of Meningococcal Serogroup C Conjugate Vaccination","volume":"59","author":"Bijlsma","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.008_b0145","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1900236","article-title":"Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia","volume":"382","author":"Marshall","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.10.008_b0150","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"issue":"39","key":"10.1016\/j.vaccine.2020.10.008_b0155","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1016\/j.vaccine.2016.08.015","article-title":"Distribution of Bexsero(R) Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation","volume":"34","author":"Brehony","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.008_b0160","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3201\/eid2404.171480","article-title":"Genomic Surveillance of 4CMenB Vaccine Antigenic Variants among Disease-Causing Neisseria meningitidis Isolates, United Kingdom, 2010\u20132016","volume":"24","author":"Rodrigues","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2020.10.008_b0165","doi-asserted-by":"crossref","first-page":"151","DOI":"10.12688\/wellcomeopenres.14859.1","article-title":"Typing complex meningococcal vaccines to understand diversity and population structure of key vaccine antigens","volume":"3","author":"Rodrigues","year":"2018","journal-title":"Wellcome Open Res"},{"issue":"29","key":"10.1016\/j.vaccine.2020.10.008_b0170","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.008_b0175","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00196-18","article-title":"Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Neisseria meningitidis Isolated from 2009 to 2013 in the Republic of Ireland","volume":"3","author":"Mulhall","year":"2018","journal-title":"mSphere"},{"issue":"9","key":"10.1016\/j.vaccine.2020.10.008_b0180","article-title":"Diversification in immunogenicity genes caused by selective pressures in invasive meningococci","volume":"6","author":"Kremer","year":"2020","journal-title":"Microb Genom"},{"issue":"2","key":"10.1016\/j.vaccine.2020.10.008_b0185","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3201\/eid2202.150369","article-title":"Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseriameningitidis W Strain, England","volume":"22","author":"Ladhani","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2020.10.008_b0190","article-title":"First real world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England","author":"Ladhani","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2020.10.008_b0195","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1073\/pnas.1521142113","article-title":"Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined","volume":"113","author":"Biagini","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.vaccine.2020.10.008_b0200","doi-asserted-by":"crossref","first-page":"e0197186","DOI":"10.1371\/journal.pone.0197186","article-title":"Clustered intergenic region sequences as predictors of factor H Binding Protein expression patterns and for assessing Neisseria meningitidis strain coverage by meningococcal vaccines","volume":"13","author":"Cayrou","year":"2018","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.vaccine.2020.10.008_b0205","doi-asserted-by":"crossref","first-page":"e65043","DOI":"10.1371\/journal.pone.0065043","article-title":"An Analysis of the Sequence Variability of Meningococcal fHbp, NadA and NHBA over a 50-Year Period in the Netherlands","volume":"8","author":"Bambini","year":"2013","journal-title":"PLoS ONE"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20312834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20312834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:48:29Z","timestamp":1759402109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20312834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":41,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0264410X20312834"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.008","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}